Promethera is currently focused on advancing cell-based medicines using its HepaStem platform into clinical trials in two disease areas, Acute-on Chronic Liver Failure (ACLF) and Nonalcoholic steatohepatitis (NASH). Both indications could benefit greatly from the combined immuno-modulatory and anti-fibrotic properties of HepaStem-derived cell lines.
Other opportunities, such as the Company’s development initiative to further augment HepaStem therapeutic potential using gene transfer as well as commercialization of the Heparesc product line will be pursued predominantly with partners.
For all its activities, Promethera is taking a global view early on to pursue a development strategy that maximizes the probability of success. Asia and in particular Japan have taken a cell therapy-friendly position years ago and represent markets of special opportunities. Promethera has benefitted from this trend in Asia already and was able to attract a significant set of both strategic and institutional investors from Japan and South Korea. The Company is committed to exploit these strong initial ties and continue expanding its network into the wider Asian region beyond Japan and South Korea.
As a group, Promethera has assembled a unique set of technological platforms supported by a broad intellectual property portfolio and an experienced international team under one roof. With the acquisition of Cytonet in 2016, the Company has added complementary liver sourcing, manufacturing capabilities and innovative cell therapies to treat inborn and acquired liver diseases.
Promethera is committed to further strengthen its research and development capabilities both through internal development activities as well as through partnerships and potentially through strategic transactions.